Early clinical studies of novel therapies for thyroid cancers

被引：37

作者：

Sherman, Steven I. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Internal Med, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2008年 / 37卷 / 02期

关键词：

D O I：

10.1016/j.ecl.2008.02.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Historically, systemic therapies for advanced, metastatic thyroid carcinomas have been poorly effective. However, as a result of a confluence of increasing knowledge of the biologic basis for thyroid cancer development and progression, identification of therapeutic agents that could target these biologic abnormalities, and enthusiasm for research by both funding agencies as well as patients, multiple clinical trials have been initiated and successfully completed during the past several years. This article focuses on findings from key studies that reflect the new paradigms for treatment.

引用

页码：511 / +

页数：15

共 73 条

[1] Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion [J].

Ain, KB ;

Egorin, MJ ;

DeSimone, PA .

THYROID, 2000, 10 (07) :587-594

[2] Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas [J].

Ain, Kenneth B. ;

Lee, Charles ;

Williams, Kevin D. .

THYROID, 2007, 17 (07) :663-670

[3] The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells [J].

Akeno-Stuart, Nagako ;

Croyle, Michelle ;

Knauf, Jeffrey A. ;

Malaguarnera, Roberta ;

Vitagliano, Donata ;

Santoro, Massimo ;

Stephan, Christine ;

Grosios, Konstantina ;

Wartmann, Markus ;

Cozens, Robert ;

Caravatti, Giorgio ;

Fabbro, Doriano ;

Lane, Heidi A. ;

Fagin, James A. .

CANCER RESEARCH, 2007, 67 (14) :6956-6964

[4]

[Anonymous], J CLIN ONCOL S

[5] Medullary thyroid cancer: therapeutic targets and molecular markers [J].

Ball, Douglas W. .

CURRENT OPINION IN ONCOLOGY, 2007, 19 (01) :18-23

[6] Pharmacology of imatinib (STI571) [J].

Buchdunger, E ;

O'Reilly, T ;

Wood, J .

EUROPEAN JOURNAL OF CANCER, 2002, 38 :S28-S36

[7]

Carlomagno F, 2002, CANCER RES, V62, P7284

[8] Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors [J].

Carlomagno, F ;

Guida, T ;

Anaganti, S ;

Vecchio, G ;

Fusco, A ;

Ryan, AJ ;

Billaud, M ;

Santoro, M .

ONCOGENE, 2004, 23 (36) :6056-6063

[9] BAY 43-9006 inhibition of oncogenic RET mutants [J].

Carlomagno, F ;

Anaganti, S ;

Guida, T ;

Salvatore, G ;

Troncone, G ;

Wilhelm, SM ;

Santoro, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05) :326-334

[10] Mechanisms of angiogenesis and arteriogenesis [J].

Carmeliet, P .

NATURE MEDICINE, 2000, 6 (04) :389-395

← 1 2 3 4 5 6 7 8 →